Workflow
临床诊断医疗产品
icon
Search documents
太湖潮涌聚新能 开放共赢链全球
Xin Hua Ri Bao· 2025-11-19 02:58
江苏以丰硕的开放成果,赢得与会嘉宾的广泛认同。数据显示,2021—2024年江苏实际使用外资累计达 1037.4亿美元,2024年实际使用外资占全国比重16.4%,今年前三季度占比提升至18.1%,规模继续保持 全国首位。全省拥有4.3万家外资企业,世界500强企业中有408家在江苏布局。 开放的成色,不仅见之于数字,更体现在制度创新与改革作为上。今年8月,《中国(江苏)自由贸易试验 区生物医药全产业链开放创新发展方案》获得国务院批复,江苏成为全国首个获批生物医药领域试点的 省份。"我们开展的这项改革,包括18项政策举措、77条具体任务,就是要为'一粒药'的研发、制造、 流通、使用打造一条'高速公路',从实验室到市场全程绿灯、畅行无阻。"省商务厅厅长、省自贸办主 任司勇在论坛上郑重推介,这条"高速公路"具备三大特征: 准入更宽——分段生产试点为企业节省约30%固定资产投入,允许使用本土人源性材料降低研发成本; 通关更快——源自研发用物品进口"白名单"扩围至全省主要城市,通关时长缩短近50%;保障更全—— 依托数据出境负面清单与"苏数通"平台将评估时间压缩30%—50%,设立产业基金、知识产权质押融资 平台等构 ...
700多名中外嘉宾齐聚无锡,共商产业链供应链协同发展之道太湖潮涌聚新能 开放共赢链全球
Xin Hua Ri Bao· 2025-11-18 23:17
Core Insights - The forum held on November 18 in Wuxi focused on international cooperation in supply chains, attracting over 700 attendees, including executives from more than 30 Fortune 500 companies [1] - Key discussions revolved around the collaborative development of supply chains in critical industries such as renewable energy and biomedicine, leading to the signing of 21 high-level R&D projects [1][6] - Jiangsu province has achieved significant foreign investment, with actual foreign capital usage reaching $103.74 billion from 2021 to 2024, accounting for 16.4% of the national total in 2024 [2] Industry Developments - The establishment of the "Jiangsu Province Biomedicine Full Industry Chain Open Innovation Alliance" and the "Jiangsu Province New Energy Industry Chain Hub Platform" aims to enhance global resource connectivity and build a new industrial ecosystem [1][6] - The "Jiangsu Free Trade Zone Biomedicine Full Industry Chain Open Innovation Development Plan" has been approved, making Jiangsu the first province in China to pilot in the biomedicine sector, featuring 18 policy measures to streamline the R&D process [3] Company Engagements - GE Healthcare's Wuxi base has become the largest ultrasound equipment center globally, supporting over 460 upstream and downstream suppliers, showcasing the strength of the industrial cluster [2] - Pfizer announced the launch of the "Pfizer-Jiangsu Full Industry Chain Innovation Empowerment Plan" to deepen its involvement in Jiangsu's biomedicine sector, emphasizing local production and global market integration [5][7] - Apple’s core suppliers, over 80% of whom have factories in China, with half located in Jiangsu, highlight the region's mature industrial chain and advancements in smart manufacturing and green transformation [4]